Symbols / AKTS Stock $19.53 -1.01% Aktis Oncology, Inc.

Healthcare • Biotechnology • United States • NMS
AKTS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Matthew Roden Ph.D.
Exch · Country NMS · United States
Market Cap 1.08B
Enterprise Value 552.66M
Income -67.07M
Sales 8.28M
FCF (ttm) —
Book/sh 9.16
Cash/sh 9.74
Employees 79
Insider 10d —
IPO Jan 09, 2026
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -9.95
PEG —
P/S 130.43
P/B 2.13
P/C —
EV/EBITDA -7.20
EV/Sales 66.77
Quick Ratio 19.37
Current Ratio 19.49
Debt/Eq 2.29
LT Debt/Eq —
EPS (ttm) -1.20
EPS next Y -1.96
EPS Growth —
Revenue Growth 123.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-05-11
ROA —
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin -7.04%
Profit Margin 0.00%
Shs Outstand 53.40M
Shs Float 26.37M
Insider Own 12.36%
Instit Own 56.12%
Short Float 16.25%
Short Ratio 8.06
Short Interest 2.57M
52W High 29.16
vs 52W High -33.02%
52W Low 14.72
vs 52W Low 32.68%
Beta —
Impl. Vol. —
Rel Volume 0.39
Avg Volume 332.82K
Volume 129.03K
Target (mean) $32.40
Tgt Median $33.00
Tgt Low $30.00
Tgt High $34.00
# Analysts 5
Recom Strong_buy
Prev Close $19.73
Price $19.53
Change -1.01%
About

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$32.40
Mean price target
2. Current target
$19.53
Latest analyst target
3. DCF / Fair value
$32.40
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$19.53
Low
$30.00
High
$34.00
Mean
$32.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-29 init William Blair — → Outperform —
2026-03-31 main HC Wainwright & Co. Buy → Buy $33
2026-03-09 init HC Wainwright & Co. — → Buy $30
2026-02-03 init Leerink Partners — → Outperform $31
2026-02-03 init JP Morgan — → Overweight $30
2024-01-04 down Piper Sandler Overweight → Neutral $1
2023-09-07 main Oppenheimer Outperform → Outperform $3
2023-09-07 down B. Riley Securities Buy → Neutral $2
2023-05-09 main Oppenheimer — → Outperform $6
2023-05-09 main Roth MKM — → Buy $5
2023-01-24 init B. Riley Securities — → Buy $9
2022-11-15 main Oppenheimer — → Outperform $7
2022-09-13 main Piper Sandler — → Overweight $5
2022-05-03 main Piper Sandler — → Overweight $7
2021-11-02 main Oppenheimer — → Outperform $13
2021-05-04 main Roth Capital — → Buy $16
2021-01-04 main Roth Capital — → Buy $16
2019-12-20 main Northland Capital Markets — → Market Perform $7
2019-09-18 down Northland Capital Markets Outperform → Market Perform —
2019-07-10 up Northland Capital Markets Market Perform → Outperform —
News
RSS: Latest AKTS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-12 FOLEY TODD Director and Beneficial Owner of more than 10% of a Class of Security — 232,870 $18.00 $4,191,660
2026-01-12 FOLEY TODD Director and Beneficial Owner of more than 10% of a Class of Security — 4,002,533 — —
2026-01-12 KIM HELEN SUSAN Director and Beneficial Owner of more than 10% of a Class of Security — 835,000 $18.00 $15,030,000
2026-01-12 KIM HELEN SUSAN Director and Beneficial Owner of more than 10% of a Class of Security — 4,994,212 — —
2026-01-12 MPM BIOVENTURES 2018, L.P. Beneficial Owner of more than 10% of a Class of Security — 1,112,777 $18.00 $20,029,986
2026-01-12 MPM BIOVENTURES 2018, L.P. Beneficial Owner of more than 10% of a Class of Security — 8,805,578 — —
2026-01-12 ECOR1 CAPITAL, L.L.C. Unknown — 2,222,222 $18.00 $39,999,996
2026-01-12 ECOR1 CAPITAL, L.L.C. Unknown — 2,602,247 — —
2026-01-12 VIDA VENTURES II, L.L.C Beneficial Owner of more than 10% of a Class of Security — 835,000 $18.00 $15,030,000
2026-01-12 VIDA VENTURES II, L.L.C Beneficial Owner of more than 10% of a Class of Security — 4,994,212 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
6.50
+336.92%
1.49
0.00
0.00
Operating Revenue
6.50
+336.92%
1.49
0.00
0.00
Operating Expense
81.18
+51.64%
53.54
+53.87%
34.79
+76.05%
19.76
Research And Development
67.45
+64.70%
40.95
+58.01%
25.92
+81.23%
14.30
Selling General And Administration
12.60
+11.42%
11.31
+47.25%
7.68
+50.39%
5.11
General And Administrative Expense
12.60
+11.42%
11.31
+47.25%
7.68
+50.39%
5.11
Salaries And Wages
7.68
+24.96%
6.14
+29.00%
4.76
+62.58%
2.93
Other Gand A
4.92
-4.69%
5.16
+77.03%
2.92
+33.99%
2.18
Total Expenses
81.18
+51.64%
53.54
+53.87%
34.79
+76.05%
19.76
Operating Income
-74.68
-43.49%
-52.05
-49.59%
-34.79
-76.05%
-19.76
Total Operating Income As Reported
-74.68
-43.49%
-52.05
-49.59%
-34.79
-76.05%
-19.76
EBITDA
-72.36
-43.35%
-50.48
-50.23%
-33.60
-73.91%
-19.32
Normalized EBITDA
-72.36
-43.37%
-50.47
-46.71%
-34.40
-76.23%
-19.52
Reconciled Depreciation
2.33
+47.87%
1.57
+40.63%
1.12
+151.69%
0.45
EBIT
-74.68
-43.49%
-52.05
-49.59%
-34.79
-76.05%
-19.76
Total Unusual Items
—
-0.01
-101.00%
0.80
+300.00%
0.20
Total Unusual Items Excluding Goodwill
—
-0.01
-101.00%
0.80
+300.00%
0.20
Net Income
-63.73
-44.91%
-43.98
-53.56%
-28.64
-59.75%
-17.93
Pretax Income
-63.73
-44.91%
-43.98
-53.56%
-28.64
-59.75%
-17.93
Net Non Operating Interest Income Expense
11.01
+35.86%
8.10
+50.70%
5.38
+226.47%
1.65
Net Interest Income
11.01
+35.86%
8.10
+50.70%
5.38
+226.47%
1.65
Interest Income Non Operating
11.01
+35.86%
8.10
+50.70%
5.38
+226.47%
1.65
Interest Income
11.01
+35.86%
8.10
+50.70%
5.38
+226.47%
1.65
Other Income Expense
-0.06
-69.70%
-0.03
-104.25%
0.78
+312.77%
0.19
Other Non Operating Income Expenses
-0.06
-124.00%
-0.03
-4.17%
-0.02
-100.00%
-0.01
Gain On Sale Of Security
—
-0.01
-101.00%
0.80
+300.00%
0.20
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-63.73
-44.91%
-43.98
-53.56%
-28.64
-59.75%
-17.93
Net Income From Continuing Operation Net Minority Interest
-63.73
-44.91%
-43.98
-53.56%
-28.64
-59.75%
-17.93
Net Income From Continuing And Discontinued Operation
-63.73
-44.91%
-43.98
-53.56%
-28.64
-59.75%
-17.93
Net Income Continuous Operations
-63.73
-44.91%
-43.98
-53.56%
-28.64
-59.75%
-17.93
Normalized Income
-63.73
-44.94%
-43.97
-49.36%
-29.44
-62.40%
-18.13
Net Income Common Stockholders
-63.73
-44.91%
-43.98
-53.56%
-28.64
-59.75%
-17.93
Diluted EPS
—
-1.26
-53.56%
-0.82
-59.75%
-0.51
Basic EPS
—
-1.26
-53.56%
-0.82
-59.75%
-0.51
Basic Average Shares
—
34.86
+0.00%
34.86
+0.00%
34.86
Diluted Average Shares
—
34.86
+0.00%
34.86
+0.00%
34.86
Diluted NI Availto Com Stockholders
-63.73
-44.91%
-43.98
-53.56%
-28.64
-59.75%
-17.93
Depreciation Amortization Depletion Income Statement
1.13
-11.29%
1.28
+6.69%
1.20
+235.96%
0.36
Depreciation And Amortization In Income Statement
1.13
-11.29%
1.28
+6.69%
1.20
+235.96%
0.36
Depreciation Income Statement
1.13
-11.29%
1.28
+6.69%
1.20
+235.96%
0.36
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
264.88
-18.79%
326.18
+166.59%
122.36
-11.54%
138.32
Current Assets
230.31
-23.45%
300.85
+200.24%
100.20
-24.36%
132.48
Cash Cash Equivalents And Short Term Investments
226.79
-23.68%
297.17
+203.66%
97.86
-23.90%
128.60
Cash And Cash Equivalents
37.78
+1.68%
37.16
+25.91%
29.51
-77.05%
128.60
Other Short Term Investments
189.00
-27.31%
260.01
+280.41%
68.35
0.00
Other Current Assets
3.52
-4.40%
3.69
+57.34%
2.34
-39.70%
3.88
Total Non Current Assets
34.58
+36.51%
25.33
+14.34%
22.15
+279.23%
5.84
Net PPE
27.25
+30.54%
20.87
-0.25%
20.92
+330.09%
4.87
Gross PPE
32.79
+36.06%
24.10
+6.75%
22.58
+318.25%
5.40
Accumulated Depreciation
-5.54
-71.72%
-3.23
-95.34%
-1.65
-210.13%
-0.53
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.82
+8.36%
0.75
+3.86%
0.73
+167.90%
0.27
Construction In Progress
7.01
+426.05%
1.33
+237.22%
0.40
-29.08%
0.56
Other Properties
24.80
+13.52%
21.85
+2.62%
21.29
+383.51%
4.40
Leases
0.17
+0.00%
0.17
+0.00%
0.17
+0.00%
0.17
Other Non Current Assets
7.33
+64.44%
4.46
+263.24%
1.23
+25.72%
0.98
Total Liabilities Net Minority Interest
411.03
-0.71%
413.98
+145.45%
168.66
+7.05%
157.55
Current Liabilities
31.24
+65.95%
18.82
+201.78%
6.24
+18.24%
5.28
Payables And Accrued Expenses
6.70
+29.62%
5.17
+93.01%
2.68
-17.07%
3.23
Payables
1.74
-9.44%
1.92
+100.42%
0.96
+95.31%
0.49
Accounts Payable
1.74
-9.44%
1.92
+100.42%
0.96
+95.31%
0.49
Current Accrued Expenses
4.96
+52.69%
3.25
+88.89%
1.72
-37.19%
2.74
Pensionand Other Post Retirement Benefit Plans Current
4.56
+47.99%
3.08
+51.70%
2.03
+70.27%
1.19
Current Debt And Capital Lease Obligation
1.31
+1.47%
1.30
-15.18%
1.53
+78.92%
0.85
Current Capital Lease Obligation
1.31
+1.47%
1.30
-15.18%
1.53
+78.92%
0.85
Current Deferred Liabilities
18.66
+101.16%
9.28
0.00
—
Current Deferred Revenue
18.66
+101.16%
9.28
0.00
—
Total Non Current Liabilities Net Minority Interest
379.80
-3.89%
395.16
+143.29%
162.42
+6.66%
152.28
Long Term Debt And Capital Lease Obligation
10.23
-4.49%
10.71
-9.77%
11.87
+1189.25%
0.92
Long Term Capital Lease Obligation
10.23
-4.49%
10.71
-9.77%
11.87
+1189.25%
0.92
Non Current Deferred Liabilities
36.16
-29.16%
51.04
0.00
—
Non Current Deferred Revenue
36.16
-29.16%
51.04
0.00
—
Other Non Current Liabilities
—
—
—
0.01
Preferred Securities Outside Stock Equity
333.41
+0.00%
333.41
+122.20%
150.05
+0.00%
150.05
Stockholders Equity
-146.15
-66.45%
-87.80
-89.61%
-46.31
-140.80%
-19.23
Common Stock Equity
-146.15
-66.45%
-87.80
-89.61%
-46.31
-140.80%
-19.23
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
52.52
+0.00%
52.52
+0.00%
52.52
+0.00%
52.52
Ordinary Shares Number
52.52
+0.00%
52.52
+0.00%
52.52
+0.00%
52.52
Additional Paid In Capital
10.37
+111.43%
4.91
+99.03%
2.46
+151.02%
0.98
Retained Earnings
-156.56
-68.65%
-92.83
-90.03%
-48.85
-141.70%
-20.21
Gains Losses Not Affecting Retained Earnings
0.04
-66.13%
0.12
+51.22%
0.08
0.00
Other Equity Adjustments
0.04
-66.13%
0.12
+51.22%
0.08
—
Total Equity Gross Minority Interest
-146.15
-66.45%
-87.80
-89.61%
-46.31
-140.80%
-19.23
Total Capitalization
-146.15
-66.45%
-87.80
-89.61%
-46.31
-140.80%
-19.23
Working Capital
199.07
-29.41%
282.03
+200.14%
93.97
-26.13%
127.21
Invested Capital
-146.15
-66.45%
-87.80
-89.61%
-46.31
-140.80%
-19.23
Total Debt
11.55
-3.85%
12.01
-10.39%
13.40
+655.04%
1.77
Capital Lease Obligations
11.55
-3.85%
12.01
-10.39%
13.40
+655.04%
1.77
Net Tangible Assets
-146.15
-66.45%
-87.80
-89.61%
-46.31
-140.80%
-19.23
Tangible Book Value
-146.15
-66.45%
-87.80
-89.61%
-46.31
-140.80%
-19.23
Derivative Product Liabilities
—
0.00
-100.00%
0.50
-61.54%
1.30
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-64.13
-534.41%
14.76
+149.20%
-30.00
-65.54%
-18.12
Cash Flow From Continuing Operating Activities
-64.13
-534.41%
14.76
+149.20%
-30.00
-65.54%
-18.12
Net Income From Continuing Operations
-63.73
-44.91%
-43.98
-53.56%
-28.64
-59.75%
-17.93
Depreciation Amortization Depletion
2.33
+47.87%
1.57
+40.63%
1.12
+151.69%
0.45
Depreciation And Amortization
2.33
+47.87%
1.57
+40.63%
1.12
+151.69%
0.45
Stock Based Compensation
5.13
+127.04%
2.26
+52.91%
1.48
+111.75%
0.70
Operating Gains Losses
—
0.01
+101.00%
-0.80
-300.00%
-0.20
Gain Loss On Investment Securities
—
0.01
+101.00%
-0.80
-300.00%
-0.20
Change In Working Capital
-3.23
-105.48%
58.98
+393300.00%
-0.01
+98.68%
-1.14
Change In Receivables
1.03
+220.09%
-0.86
-235.02%
-0.26
0.00
Change In Prepaid Assets
-0.87
-80.91%
-0.48
-281.89%
0.27
+107.33%
-3.62
Change In Payables And Accrued Expense
2.16
-14.17%
2.51
+481.48%
0.43
-82.97%
2.54
Change In Accrued Expense
2.20
+2.23%
2.15
+1048.02%
-0.23
-108.95%
2.54
Change In Payable
-0.04
-112.22%
0.36
-45.37%
0.66
+66000.00%
-0.00
Change In Account Payable
-0.04
-112.22%
0.36
-45.37%
0.66
+66000.00%
-0.00
Change In Other Working Capital
-5.50
-109.40%
58.51
—
—
Change In Other Current Assets
1.35
+64.51%
0.82
-55.17%
1.83
+260.75%
0.51
Change In Other Current Liabilities
-1.40
+7.95%
-1.52
+33.36%
-2.28
-303.53%
-0.57
Investing Cash Flow
65.96
+134.64%
-190.40
-176.63%
-68.83
-2883.44%
-2.31
Cash Flow From Continuing Investing Activities
65.96
+134.64%
-190.40
-176.63%
-68.83
-2883.44%
-2.31
Net PPE Purchase And Sale
-9.58
-234.87%
-2.86
+22.79%
-3.71
-60.68%
-2.31
Purchase Of PPE
-9.58
-234.87%
-2.86
+23.96%
-3.76
-63.16%
-2.31
Sale Of PPE
—
0.00
-100.00%
0.06
0.00
Capital Expenditure
-9.58
-234.87%
-2.86
+23.96%
-3.76
-63.16%
-2.31
Net Investment Purchase And Sale
75.55
+140.28%
-187.54
-187.98%
-65.12
0.00
Purchase Of Investment
-193.87
+32.78%
-288.40
-97.79%
-145.81
0.00
Sale Of Investment
269.42
+167.12%
100.86
+25.00%
80.69
0.00
Financing Cash Flow
-1.21
-100.66%
183.28
0.00
-100.00%
119.98
Cash Flow From Continuing Financing Activities
-1.21
-100.66%
183.28
0.00
-100.00%
119.98
Proceeds From Stock Option Exercised
0.34
+87.71%
0.18
0.00
—
Net Other Financing Charges
-1.55
+18.31%
-1.90
—
-0.15
Changes In Cash
0.62
-91.83%
7.65
+107.74%
-98.83
-199.28%
99.55
Beginning Cash Position
38.31
+24.94%
30.66
-76.32%
129.49
+332.48%
29.94
End Cash Position
38.93
+1.63%
38.31
+24.94%
30.66
-76.32%
129.49
Free Cash Flow
-73.71
-719.42%
11.90
+135.24%
-33.77
-65.27%
-20.43
Amortization Of Securities
-4.62
-13.31%
-4.08
-29.72%
-3.15
0.00
Issuance Of Capital Stock
0.00
-100.00%
185.00
0.00
-100.00%
120.14
Net Preferred Stock Issuance
0.00
-100.00%
185.00
0.00
-100.00%
120.14
Preferred Stock Issuance
0.00
-100.00%
185.00
0.00
-100.00%
120.14
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category